Dexpramipexole

Generic Name: Dexpramipexole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N_₃S

CAS Number: 104632-28-2

Unique Ingredient Identifier: WI638GUS96

Background: Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Phase 2

Completed

Conditions: Eosinophilic Asthma
Asthma

Interventions: Drug: Placebo
Drug: Dexpramipexole

First Posted Date: 2019-08-06

Last Posted Date: 2023-04-13

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 534

Registration Number: NCT04046939

Locations: 🇺🇸
Research Site, El Paso, Texas, United States
🇺🇸
Research site, Plymouth, Minnesota, United States

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

Phase 2

Completed

Conditions: Chronic Sinusitis With Nasal Polyps and Eosinophilia

Interventions: Drug: dexpramipexole

First Posted Date: 2014-08-15

Last Posted Date: 2021-05-18

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 20

Registration Number: NCT02217332

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
ENT Associates of South Florida, Boca Raton, Florida, United States

and more 4 locations

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Phase 2

Conditions: Hypereosinophilic Syndrome

Interventions: Drug: Dexpramipexole

First Posted Date: 2014-04-02

Last Posted Date: 2017-12-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT02101138

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 3 Extension Study of Dexpramipexole in ALS

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dexpramipexole

First Posted Date: 2012-06-18

Last Posted Date: 2022-05-03

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 616

Registration Number: NCT01622088

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
ALS Center at Penn, Philadelphia, Pennsylvania, United States

and more 77 locations

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dexpramipexole

First Posted Date: 2012-05-28

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 24

Registration Number: NCT01607034

Locations: 🇺🇸
Research Site, St. Paul, Minnesota, United States

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dexpramipexole
Drug: Warfarin

First Posted Date: 2012-05-14

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 15

Registration Number: NCT01597310

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Cimetidine plus Dexpramipexole
Drug: Dexpramipexole

First Posted Date: 2012-02-22

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 14

Registration Number: NCT01536249

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dexpramipexole Placebo
Drug: Moxifloxacin
Drug: Dexpramipexole

First Posted Date: 2012-01-18

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 68

Registration Number: NCT01511029

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Dexpramipexole SAD/MAD Study

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dexpramipexole Placebo
Drug: Dexpramipexole

First Posted Date: 2011-10-10

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 63

Registration Number: NCT01449578

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Phase 3 Study of Dexpramipexole in ALS

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: Dexpramipexole

First Posted Date: 2011-01-21

Last Posted Date: 2021-06-07

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 942

Registration Number: NCT01281189

Locations: 🇧🇪
AZ St-Lucas, Gent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 79 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy